Green J, Debby H, Lederer E, Levi M, Zajicek H K, Bick T
Department of Nephrology, Rambam Medical Center, B. Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel.
Kidney Int. 2001 Sep;60(3):1182-96. doi: 10.1046/j.1523-1755.2001.0600031182.x.
Patients undergoing successful kidney transplantation often manifest overt hypophosphatemia associated with exaggerated phosphaturia during the early post-transplant period (2 weeks to 3 months). The mechanism for this phenomenon has not been fully elucidated. We tested the hypothesis that a circulating serum factor [non-parathyroid hormone (non-PTH)], which operates during chronic renal failure (CRF) to maintain phosphate (Pi) homeostasis, can increase fractional excretion of Pi (FE(PO4)) in normal functioning kidney grafts during the early post-transplant period, thereby causing phosphaturia and hypophosphatemia.
Five groups of patients were studied: control subjects (group 1, N = 16), "early" (2 weeks to 1 month) post-transplant patients (group 2, N = 22), "late" (9 to 12 months) post-transplant patients (group 3, N = 14), patients with advanced CRF (glomerular filtration rate = 30 to 40 mL/min; group 4, N = 8), and patients who suffered from end-stage renal failure and were treated by chronic hemodialysis (group 5, N = 14). Group 2 manifested significant hypophosphatemia and phosphaturia when compared with groups 1 and 3 (Pi = 0.9 +/- 0.003 mg/dL, FE(PO4) = 68+/- 5%, P < 0.0005 vs. groups 1 and 3). Sera were taken from each of the five subject groups and applied to the proximal tubular opossum kidney (OK) cells. The activity of Na/Pi-type 4 (that is, OK-specific type II transporter) was evaluated by measuring Na(+)-dependent (32)Pi flux. The expression of Na/Pi type II mRNA and the abundance of Na/Pi protein were determined by Northern and Western blot assays, respectively.
When compared with sera from groups 1 and 3, 10% sera taken from groups 2, 4, and 5 (incubated overnight with OK cells) inhibited (32)Pi flux by 25 to 30% (P < 0.0003). Both Na/Pi mRNA and the expression of Na/Pi protein were markedly augmented under the same conditions (P < 0.05 groups 2, 4, and 5 vs. groups 1 and 3). Time-course analysis revealed that the up-regulation of Na/Pi protein by sera from groups 2, 4, and 5 was observed as early as four hours of incubation, whereas augmented abundance of Na/Pi mRNA was only seen after eight hours of incubation. The addition of PTH (1-34) to sera from groups 2, 4, and 5 abolished the augmented expression of NaPi protein. We labeled OK cell surface membrane proteins with N-hydroxysuccinimide bound to biotin (NHS-SS-biotin). Biotinylated transporters incubated with the different sera were precipitated by strepavidin and identified by Western blot analysis. Cells incubated in sera from group 2 showed increased membrane bound transporter when compared with control sera, whereas the intracellular pool of the transporter was comparable between the two groups.
A non-PTH circulating serum factor (possibly phosphatonin) that increases FE(PO4) during CRF is also responsible for phosphaturia and hypophosphatemia in the early period following successful kidney transplantation. The putative factor inactivates Na/Pi activity along with inhibition of the transporter trafficking from the cell membrane into the cytosol.
成功接受肾移植的患者在移植后的早期阶段(2周-3个月)常表现出明显的低磷血症,并伴有磷尿症加重。这种现象的机制尚未完全阐明。我们检验了这样一个假设,即在慢性肾衰竭(CRF)期间发挥作用以维持磷酸盐(Pi)稳态的一种循环血清因子[非甲状旁腺激素(non-PTH)],在移植后的早期阶段可增加正常功能肾移植中的Pi分数排泄(FE(PO4)),从而导致磷尿症和低磷血症。
对五组患者进行了研究:对照组(第1组,N = 16)、移植后“早期”(2周-1个月)患者(第2组,N = 22)、移植后“晚期”(9-12个月)患者(第3组,N = 14)、晚期CRF患者(肾小球滤过率 = 30-40 mL/min;第4组,N = 8)以及终末期肾衰竭且接受慢性血液透析治疗的患者(第5组,N = 14)。与第1组和第3组相比,第2组表现出明显的低磷血症和磷尿症(Pi = 0.9 +/- 0.003 mg/dL,FE(PO4) = 68 +/- 5%,与第1组和第3组相比,P < 0.0005)。从五个受试者组中分别采集血清,并应用于近端肾小管负鼠肾(OK)细胞。通过测量Na(+)依赖性(32)Pi通量来评估Na/Pi-4型(即OK特异性II型转运体)的活性。分别通过Northern印迹和Western印迹分析来测定Na/Pi II型mRNA的表达和Na/Pi蛋白的丰度。
与第1组和第3组的血清相比,第2、4和5组的10%血清(与OK细胞孵育过夜)使(32)Pi通量降低了25%-30%(P < 0.0003)。在相同条件下,Na/Pi mRNA和Na/Pi蛋白的表达均显著增加(第2、4和5组与第1组和第3组相比,P < 0.05)。时间进程分析显示,第2、4和5组血清对Na/Pi蛋白的上调在孵育4小时时即可观察到,而Na/Pi mRNA丰度的增加仅在孵育8小时后才出现。向第2、4和5组的血清中添加PTH(1-34)可消除NaPi蛋白表达的增加。我们用与生物素结合的N-羟基琥珀酰亚胺(NHS-SS-生物素)标记OK细胞表面膜蛋白。与不同血清孵育的生物素化转运体通过链霉抗生物素蛋白沉淀,并通过Western印迹分析进行鉴定。与对照血清相比,在第2组血清中孵育的细胞显示膜结合转运体增加,而两组之间转运体的细胞内池相当。
一种在CRF期间增加FE(PO4)的非PTH循环血清因子(可能是磷调素)也导致了成功肾移植后早期的磷尿症和低磷血症。该假定因子使Na/Pi活性失活,并抑制转运体从细胞膜向细胞质的转运。